ADMA Biologics logo

ADMA BiologicsNASDAQ: ADMA

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

17 October 2013

Next earnings report:

08 November 2024

Last dividends:

N/A

Next dividends:

N/A
$4.47 B
-7%vs. 3y high
88%vs. sector
136.93
-7%vs. 3y high
93%vs. sector
-7%vs. 3y high
98%vs. sector
-7%vs. 3y high
80%vs. sector

Price

pre-market | 96 min ago
$19.17-$0.21(-1.08%)

Dividend

No data over the past 3 years
$107.19 M$105.85 M
$107.19 M$32.06 M

Analysts recommendations

Institutional Ownership

ADMA Latest News

ADMA INQUIRY ALERT: A Securities Fraud Investigation has been Initiated against ADMA Biologics into the Auditor Resignation; Investors with Losses are Urged to Contact the Firm (Nasdaq:ADMA)
globenewswire.com04 November 2024 Sentiment: -

NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc.

BFA Law is Investigating ADMA BIOLOGICS for Securities Fraud after Stock Plummets 20%; Contact the Firm if You Suffered Losses (Nasdaq:ADMA)
globenewswire.com02 November 2024 Sentiment: NEGATIVE

NEW YORK, Nov. 02, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
prnewswire.com02 November 2024 Sentiment: NEGATIVE

NEW YORK , Nov. 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

ADMA INVESTIGATION NOTE: Contact BFA Law about ADMA Biologics Securities Fraud Investigation into Auditor Resignation (Nasdaq:ADMA)
accesswire.com01 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 1, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
accesswire.com31 October 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / October 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ:ADMA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

ADMA INVESTIGATION: ADMA Biologics Investors with Losses are Notified to Contact BFA Law about Ongoing Securities Fraud Investigation into Auditor Resignation (Nasdaq:ADMA)
globenewswire.com31 October 2024 Sentiment: NEGATIVE

NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc.

Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider
zacks.com29 October 2024 Sentiment: POSITIVE

Adma Biologics (ADMA) concluded the recent trading session at $16.71, signifying a +1.7% move from its prior day's close.

ADMA Biologics to Report Third Quarter 2024 Financial Results on November 7, 2024
globenewswire.com29 October 2024 Sentiment: NEUTRAL

RAMSEY, N.J. and BOCA RATON, Fla.

ADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into ADMA Biologics Inc and Encourages Investors to Contact the Firm
businesswire.com28 October 2024 Sentiment: NEGATIVE

NEW YORK--(BUSINESS WIRE)---- $ADMA #ADMA--Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ADMA Biologics Inc (“ADMA Biologics” or “the Company”) (NASDAQ: ADMA). Investors who purchased ADMA Biologics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ADMA. Investigation Details On October 9, 2024, ADMA Biologics disclosed the abrupt resignation of its independ.

ADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into ADMA Biologics Inc and Encourages Investors to Contact the Firm
globenewswire.com27 October 2024 Sentiment: NEGATIVE

NEW YORK, Oct. 27, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ADMA Biologics Inc (“ADMA Biologics” or “the Company”) (NASDAQ: ADMA). Investors who purchased ADMA Biologics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ADMA.

What type of business is ADMA Biologics?

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

What sector is ADMA Biologics in?

ADMA Biologics is in the Healthcare sector

What industry is ADMA Biologics in?

ADMA Biologics is in the Biotechnology industry

What country is ADMA Biologics from?

ADMA Biologics is headquartered in United States

When did ADMA Biologics go public?

ADMA Biologics initial public offering (IPO) was on 17 October 2013

What is ADMA Biologics website?

https://www.admabiologics.com

Is ADMA Biologics in the S&P 500?

No, ADMA Biologics is not included in the S&P 500 index

Is ADMA Biologics in the NASDAQ 100?

No, ADMA Biologics is not included in the NASDAQ 100 index

Is ADMA Biologics in the Dow Jones?

No, ADMA Biologics is not included in the Dow Jones index

When was ADMA Biologics the previous earnings report?

No data

When does ADMA Biologics earnings report?

The next expected earnings date for ADMA Biologics is 08 November 2024